

June 9, 2016



Actinium Announces Strong Presence at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

NEW YORK, NY -- (Marketwired) -- 06/09/16 --

- Company will host an educational event on Monday, June 13th focused on the upcoming lomab-B Phase 3 SIERRA trial and alpha particle radioimmunotherapy
- Dr. Joseph Jurcic, Director of Hematologic Malignancies at Columbia University Medical Center will lead lomab-B session and Dr. Chaitanya Divgi, Director, Nuclear Medicine and PET Center, Columbia University will lead alpha radioimmunotherapy session
- Actinium management team will be holding meetings with physicians and representatives from other companies at corporate exhibition booth

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of patients with advanced cancers, today announced its presence at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held June 11 - 15, 2016 in San Diego, California. Representatives from Actinium's executive management team will be on hand to conduct meetings with nuclear medicine physicians and company representatives attending the SNMMI Annual Meeting. In addition, the Company will be hosting an educational event on Monday, June 13, 2016 focused on lomab-B, which will soon begin the pivotal Phase 3 SIERRA trial in patients with relapsed or refractory acute myeloid leukemia (AML) who are over the age of 55 prior to a bone marrow transplant (BMT), and alpha particle radioimmunotherapy, which is the basis of Actinium's Actimab-A therapy that is being studied in a Phase 1/2 trial in patients newly diagnosed with AML who are over the age of 60.

Sandesh Seth, Actinium's Executive Chairman stated, "The Society of Nuclear Medicine and Molecular Imaging Annual Meeting represents an exciting conference for Actinium and we are excited by our significant presence this year. The interest in our educational event has been overwhelming, which we believe speaks to the attractiveness of lomab-B and Actimab-A to this physician community, one that is integral to Actinium, our therapies and their intended patients."

Meeting attendees interested in attending Actinium's educational event should contact David Gould, Senior Vice President, Corporate Development and Corporate Affairs at dgould@actiniumpharma.com.

About lomab-B

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for a hematopoietic stem cell transplantation, referred to as a bone marrow transplant, in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is currently in a single arm, multicenter trial Phase 1/2 trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, lintuzumab, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial

performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals